Key result
The Symplicity HTN-3 trial demonstrates the critical importance of randomization and blinding when evaluating new treatments for hypertension.
Key points are not available for this paper at this time.
Design
Editorial
Highlights the importance of randomization and blinding in clinical trials, using the Symplicity HTN-3 trial as an example.
Symplicity HTN-3 illustrates the importance of randomisation and blinding for exciting new treatments
No takes yet. Share an insight, caveat, or question.
Shun‐Shin et al. (2014) studied this question. The Symplicity HTN-3 trial demonstrates the critical importance of randomization and blinding when evaluating new treatments for hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: